ALN HTT02
Alternative Names: ALN-HTT-02Latest Information Update: 12 Sep 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Huntingtin protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 12 Sep 2024 Alnylam Pharmaceuticals plans a phase I trial for Huntington's disease (Intrathecal) in September 2024 (NCT06585449)
- 02 May 2024 Preclinical trials in Huntington's disease in USA (Parenteral) prior to May 2024
- 01 Mar 2024 Pharmacodynamics data from preclinical studies in Huntington's disease released by Alnylam Pharmaceuticals